Published in Circ Res on December 18, 2008
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Circulation (2016) 2.71
Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res (2011) 2.02
Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol (2013) 1.99
Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail (2010) 1.82
Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res (2013) 1.72
Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation (2010) 1.71
Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail (2009) 1.70
Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci (2009) 1.67
Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J Biol Chem (2010) 1.52
Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol (2012) 1.46
Mitochondria and cardiovascular aging. Circ Res (2012) 1.46
Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes (2011) 1.44
Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail (2012) 1.36
AMP-activated protein kinase regulation and biological actions in the heart. Circ Res (2012) 1.33
Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol (2012) 1.29
Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol (2010) 1.18
Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc (2013) 1.18
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol (2011) 1.17
Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem (2010) 1.16
Autophagy in cardiovascular biology. J Clin Invest (2015) 1.14
AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. Aging Cell (2010) 1.14
Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. Am J Physiol Heart Circ Physiol (2013) 1.12
AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res (2012) 1.10
Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J Am Coll Cardiol (2010) 1.09
Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol (2010) 1.04
The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.04
Mitochondrial dysfunction in heart failure. Heart Fail Rev (2013) 1.02
AMP activated protein kinase-α2 regulates expression of estrogen-related receptor-α, a metabolic transcription factor related to heart failure development. Hypertension (2011) 1.01
The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes. Am J Physiol Heart Circ Physiol (2015) 0.99
Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert Rev Cardiovasc Ther (2010) 0.97
Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther (2012) 0.94
Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes (2012) 0.94
Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J Cell Mol Med (2014) 0.93
The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats. Int J Mol Sci (2012) 0.92
Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J Biol Chem (2011) 0.92
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One (2010) 0.90
Rescue of Heart Failure by Mitochondrial Recovery. Int Neurourol J (2016) 0.89
Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate. Cell Death Differ (2012) 0.89
Preservation of cellular glutathione status and mitochondrial membrane potential by N-acetylcysteine and insulin sensitizers prevent carbonyl stress-induced human brain endothelial cell apoptosis. Curr Neurovasc Res (2009) 0.89
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res (2016) 0.89
Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev (2012) 0.88
Autophagy, myocardial protection, and the metabolic syndrome. J Cardiovasc Pharmacol (2012) 0.88
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One (2014) 0.87
Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc (2014) 0.87
AMPK isoform expression in the normal and failing hearts. J Mol Cell Cardiol (2012) 0.87
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice. Korean J Physiol Pharmacol (2010) 0.86
Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin (2011) 0.85
Metformin in Diabetic Patients with Heart Failure: Safe and Effective? Curr Cardiovasc Risk Rep (2013) 0.85
Potential biomarker of metformin action. J Endocrinol (2014) 0.84
Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice. Cardiovasc Diabetol (2016) 0.84
Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. Cardiorenal Med (2012) 0.84
Does long-term metformin treatment increase cardiac lipoprotein lipase? Metabolism (2010) 0.83
Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2. Hypertension (2014) 0.83
Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies. J Cardiovasc Pharmacol (2014) 0.82
Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol (2014) 0.82
Cardiac Fibrosis Alleviated by Exercise Training Is AMPK-Dependent. PLoS One (2015) 0.81
Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study. PLoS One (2014) 0.79
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia. Lipids Health Dis (2014) 0.79
Metformin increases degradation of phospholamban via autophagy in cardiomyocytes. Proc Natl Acad Sci U S A (2015) 0.79
NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1α expression levels during hypoxia/reoxygenation injury. Korean J Physiol Pharmacol (2016) 0.79
LKB1/Mo25/STRAD uniquely impacts sarcomeric contractile function and posttranslational modification. Biophys J (2015) 0.79
Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement. Am J Cardiol (2012) 0.79
5'-AMP Activated Protein Kinase is Involved in the Regulation of Myocardial β-Oxidative Capacity in Mice. Front Physiol (2012) 0.79
Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects. Br J Pharmacol (2014) 0.79
Enhancement of Glucose Metabolism via PGC-1α Participates in the Cardioprotection of Chronic Intermittent Hypobaric Hypoxia. Front Physiol (2016) 0.79
AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. Cardiovasc Res (2015) 0.78
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res (2016) 0.78
Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol (2016) 0.78
The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal (2015) 0.78
An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus. J Diabetes Res (2016) 0.77
Metformin: Midlife maturity, maiden charm. Indian J Endocrinol Metab (2012) 0.77
Renoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 &2 and AMP-activated Protein Kinase in the Kidney. Sci Rep (2016) 0.77
Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes. PLoS One (2017) 0.75
AMP-dependent protein kinase activators: not just for diabetes? Circ Res (2009) 0.75
Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium. Cardiovasc Res (2017) 0.75
Possible Role of Interaction between PPARα and Cyclophilin D in Cardioprotection of AMPK against In Vivo Ischemia-Reperfusion in Rats. PPAR Res (2016) 0.75
Metformin promotes the survival of transplanted cardiosphere-derived cells thereby enhancing their therapeutic effect against myocardial infarction. Stem Cell Res Ther (2017) 0.75
Resveratrol Reverses Functional Chagas Heart Disease in Mice. PLoS Pathog (2016) 0.75
Effect of AMP-activated protein kinase activation on cardiac fibroblast proliferation induced by coxsackievirus B3. Exp Ther Med (2016) 0.75
Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo: a prospective randomized open, blinded-endpoint study. PLoS One (2014) 0.75
Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. Exp Ther Med (2015) 0.75
Treatment strategies for the prevention of heart failure. Curr Heart Fail Rep (2013) 0.75
Treating percutaneous coronary intervention-related myocardial injury with metformin. Cardiology (2013) 0.75
A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction. PLoS One (2017) 0.75
Metformin attenuates ER stress-induced mitochondrial dysfunction. Transl Res (2017) 0.75
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A (2007) 8.23
Metformin. N Engl J Med (1996) 7.66
Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest (2000) 7.06
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest (2006) 6.85
AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A (2002) 5.93
The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci (2004) 5.65
Metformin: an update. Ann Intern Med (2002) 5.62
Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A (2007) 5.36
Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology (2003) 5.09
Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab (2005) 4.65
AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest (2004) 4.54
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol (2000) 3.27
Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes (2007) 2.45
Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A (2004) 2.44
Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation (1991) 2.28
Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem (2003) 2.23
Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem (2003) 2.07
Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation (2007) 1.86
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation (2007) 1.81
Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A (2003) 1.62
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism (2004) 1.36
Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol (2008) 1.35
Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol (1992) 1.29
Metformin in heart failure. Diabetes Care (2007) 1.29
Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol (2007) 1.24
Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol (1994) 1.21
AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol (2006) 1.14
Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury. Circ Res (2007) 1.08
Metformin improves cardiac functional recovery after ischemia in rats. Horm Metab Res (2002) 1.03
Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy. Ann Thorac Surg (1995) 0.96
Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol (2000) 0.92
Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes. Am J Physiol Heart Circ Physiol (2007) 0.87
The safety of metformin in heart failure. Ann Pharmacother (2007) 0.81
Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A (2007) 5.36
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Point: twin dogmas of maintenance of certification. J Am Coll Radiol (2015) 3.30
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation (2002) 3.11
Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res (2009) 2.83
Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes (2011) 2.72
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology (2007) 2.66
Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab (2006) 2.62
Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes (2007) 2.45
Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol (2009) 2.29
Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation (2007) 2.26
Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol (2008) 2.19
Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem (2003) 2.07
Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2007) 2.02
Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension (2004) 1.99
Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res (2008) 1.98
Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol (2003) 1.97
Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci U S A (2008) 1.87
Inhibition of integrin alphavbeta3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Stroke (2006) 1.85
Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol (2011) 1.83
Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci U S A (2012) 1.80
Novel insights into hydrogen sulfide--mediated cytoprotection. Antioxid Redox Signal (2010) 1.79
Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation (2009) 1.75
Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab (2013) 1.74
Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circ Heart Fail (2011) 1.72
Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation (2010) 1.71
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation (2013) 1.65
AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation (2009) 1.65
Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A (2003) 1.62
AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels. J Cell Physiol (2007) 1.58
A fluorescent probe for fast and quantitative detection of hydrogen sulfide in blood. Angew Chem Int Ed Engl (2011) 1.58
Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A (2014) 1.58
Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res (2013) 1.56
Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol (2002) 1.56
Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation (2009) 1.55
Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res (2010) 1.55
Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol (2006) 1.49
Nitrite supplementation reverses vascular endothelial dysfunction and large elastic artery stiffness with aging. Aging Cell (2011) 1.49
HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res (2007) 1.48
An extrasolar planet that transits the disk of its parent star. Nature (2003) 1.42
Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest (2007) 1.40
eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ Res (2006) 1.39
Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res (2012) 1.35
Exercise protects against myocardial ischemia-reperfusion injury via stimulation of β(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res (2011) 1.35
Genetic overexpression of eNOS attenuates hepatic ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 1.33
Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci (Lond) (2011) 1.32
Hydrogen sulfide and ischemia-reperfusion injury. Pharmacol Res (2010) 1.31
Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci U S A (2008) 1.31
Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation (2005) 1.31
Glucose metabolism and cardiac hypertrophy. Cardiovasc Res (2011) 1.28
Dietary nitrite restores NO homeostasis and is cardioprotective in endothelial nitric oxide synthase-deficient mice. Free Radic Biol Med (2008) 1.27
Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ Res (2014) 1.24
Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke (2005) 1.24
Inhibition of apoptosis by hyperbaric oxygen in a rat focal cerebral ischemic model. J Cereb Blood Flow Metab (2003) 1.23
Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys (2006) 1.23
Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab (2005) 1.22
Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest (2011) 1.21
Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol (2005) 1.20
Vasospasm and p53-induced apoptosis in an experimental model of subarachnoid hemorrhage. Stroke (2006) 1.20
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation (2005) 1.18
Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio (2007) 1.18
Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol (2010) 1.18
Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway. Arterioscler Thromb Vasc Biol (2007) 1.18
The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ Physiol (2012) 1.17
Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol (2013) 1.16
Myocardial protection by nitrite. Cardiovasc Res (2009) 1.16
Statins as potent antiinflammatory drugs. Circulation (2002) 1.16
p53 may play an orchestrating role in apoptotic cell death after experimental subarachnoid hemorrhage. Neurosurgery (2007) 1.14
Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol (2005) 1.14
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol (2002) 1.13
Gene therapy for ischemic heart disease. J Mol Cell Cardiol (2010) 1.11
Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res (2009) 1.10